233 related articles for article (PubMed ID: 32531869)
1. Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance.
Tomer A; Nieboer D; Roobol MJ; Bjartell A; Steyerberg EW; Rizopoulos D;
BJU Int; 2021 Jan; 127(1):96-107. PubMed ID: 32531869
[TBL] [Abstract][Full Text] [Related]
2. Personalized Decision Making for Biopsies in Prostate Cancer Active Surveillance Programs.
Tomer A; Rizopoulos D; Nieboer D; Drost FJ; Roobol MJ; Steyerberg EW
Med Decis Making; 2019 Jul; 39(5):499-508. PubMed ID: 31319751
[No Abstract] [Full Text] [Related]
3. Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts.
Drost FH; Nieboer D; Morgan TM; Carroll PR; Roobol MJ;
Eur Urol; 2019 Nov; 76(5):693-702. PubMed ID: 31451332
[TBL] [Abstract][Full Text] [Related]
4. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
[TBL] [Abstract][Full Text] [Related]
5. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
6. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
Cooperberg MR; Brooks JD; Faino AV; Newcomb LF; Kearns JT; Carroll PR; Dash A; Etzioni R; Fabrizio MD; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW; Zheng Y
Eur Urol; 2018 Aug; 74(2):211-217. PubMed ID: 29433975
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.
Lin DW; Newcomb LF; Brown MD; Sjoberg DD; Dong Y; Brooks JD; Carroll PR; Cooperberg M; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y;
Eur Urol; 2017 Sep; 72(3):448-454. PubMed ID: 27889277
[TBL] [Abstract][Full Text] [Related]
8. Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database.
Beckmann KR; Bangma CH; Helleman J; Bjartell A; Carroll PR; Morgan T; Nieboer D; Santaolalla A; Trock BJ; Valdagni R; Roobol MJ;
Prostate; 2022 May; 82(7):876-879. PubMed ID: 35254666
[TBL] [Abstract][Full Text] [Related]
9. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
[TBL] [Abstract][Full Text] [Related]
10. Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative.
Kalapara AA; Verbeek JFM; Nieboer D; Fahey M; Gnanapragasam V; Van Hemelrijck M; Lee LS; Bangma CH; Steyerberg EW; Harkin T; Helleman J; Roobol MJ; Frydenberg M;
Eur Urol Oncol; 2020 Feb; 3(1):80-91. PubMed ID: 31564531
[TBL] [Abstract][Full Text] [Related]
11. A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer.
Blute ML; Shiau JM; Truong M; Shi F; Abel EJ; Downs TM; Jarrard DF
World J Urol; 2017 May; 35(5):729-735. PubMed ID: 27631325
[TBL] [Abstract][Full Text] [Related]
12. Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.
Inoue LYT; Lin DW; Newcomb LF; Leonardson AS; Ankerst D; Gulati R; Carter HB; Trock BJ; Carroll PR; Cooperberg MR; Cowan JE; Klotz LH; Mamedov A; Penson DF; Etzioni R
Ann Intern Med; 2018 Jan; 168(1):1-9. PubMed ID: 29181514
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
[TBL] [Abstract][Full Text] [Related]
14. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
[TBL] [Abstract][Full Text] [Related]
15. Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer.
Jayadevan R; Felker ER; Kwan L; Barsa DE; Zhang H; Sisk AE; Delfin M; Marks LS
JAMA Netw Open; 2019 Sep; 2(9):e1911019. PubMed ID: 31509206
[TBL] [Abstract][Full Text] [Related]
16. Prediction of the Pathologic Gleason Score to Inform a Personalized Management Program for Prostate Cancer.
Coley RY; Zeger SL; Mamawala M; Pienta KJ; Carter HB
Eur Urol; 2017 Jul; 72(1):135-141. PubMed ID: 27523594
[TBL] [Abstract][Full Text] [Related]
17. Comparison of biopsy under-sampling and annual progression using hidden markov models to learn from prostate cancer active surveillance studies.
Li W; Denton BT; Nieboer D; Carroll PR; Roobol MJ; Morgan TM;
Cancer Med; 2020 Dec; 9(24):9611-9619. PubMed ID: 33159431
[TBL] [Abstract][Full Text] [Related]
18. Nine-year Follow-up for a Study of Diffusion-weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort.
Henderson DR; de Souza NM; Thomas K; Riches SF; Morgan VA; Sohaib SA; Dearnaley DP; Parker CC; van As NJ
Eur Urol; 2016 Jun; 69(6):1028-33. PubMed ID: 26482887
[TBL] [Abstract][Full Text] [Related]
19. Factors predicting prostate cancer upgrading on magnetic resonance imaging-targeted biopsy in an active surveillance population.
Lai WS; Gordetsky JB; Thomas JV; Nix JW; Rais-Bahrami S
Cancer; 2017 Jun; 123(11):1941-1948. PubMed ID: 28140460
[TBL] [Abstract][Full Text] [Related]
20. Negative first follow-up prostate biopsy on active surveillance is associated with decreased risk of upgrading, suspicion of progression and converting to active treatment.
Singh S; Sandhu P; Beckmann K; Santaolalla A; Dewan K; Clovis S; Rusere J; Zisengwe G; Challacombe B; Brown C; Cathcart P; Popert R; Dasgupta P; Van Hemelrijck M; Elhage O
BJU Int; 2021 Jul; 128(1):72-78. PubMed ID: 33098158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
